A cardiac glycoside HTF-1 isolated from Helleborus thibetanus Franch displays potent in vitro anti-cancer activity...

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Cancer Biology

Background:

• Cardiac glycosides (CGs) are a class of compounds with diverse biological activities.
• Discovering novel anti-cancer agents from natural sources is crucial for drug development.
• Helleborus thibetanus Franch. is a plant endemic to China with potential medicinal properties.

Purpose of the Study:

• To isolate and characterize a novel cardiac glycoside from Helleborus thibetanus.
• To evaluate the anti-cancer activity of the isolated compound HTF-1 in vitro.
• To elucidate the molecular mechanisms underlying HTF-1's anti-cancer effects.

Main Methods:

• Isolation and structural identification of HTF-1 from Helleborus thibetanus.
• In vitro cancer cell line models were used to assess HTF-1's efficacy.
• Apoptosis assays, cell cycle analysis, proliferation, migration, and invasion assays were performed.
• Western blotting was used to analyze key signaling pathways (caspase-9, JNK, ERK, PI3K-Akt-mTOR) and DNA damage.

Main Results:

• A novel cardiac glycoside, HTF-1, was isolated and identified.
• HTF-1 demonstrated potent, dose- and time-dependent apoptosis induction in various cancer cell lines.
• HTF-1 inhibited cancer cell proliferation, migration, and invasion, and caused G1 cell cycle arrest.
• HTF-1 triggered caspase-9 dependent apoptosis and double-strand DNA breaks, while modulating JNK, ERK, and PI3K-Akt-mTOR pathways.

Conclusions:

• HTF-1 possesses significant anti-cancer activity through multiple mechanisms, including apoptosis induction and cell cycle arrest.
• This novel cardiac glycoside represents a promising candidate for natural product-based anti-cancer drug development.
• The findings expand the understanding of cardiac glycosides' therapeutic potential in oncology.